Trends in Anesthesiology

A National Institutes of Health (NIH)-funded study revealed that a weekly injection of semaglutide is safe and reduces liver fat by 31% in individuals with HIV and metabolic dysfunction-associated steatotic liver disease (MASLD). MASLD, previously known as nonalcoholic fatty liver disease, is a common chronic liver disease associated with obesity, type 2 diabetes, and metabolic disorders. Semaglutide, an antidiabetic and anti-obesity medication, was self-administered by participants ages 18 and older whose HIV viral load was suppressed by antiretroviral therapy. Results showed a significant reduction in liver fat content, with 29% of participants experiencing a complete resolution of MASLD, alongside weight loss and improved metabolic markers. Although some experienced gastrointestinal side effects, semaglutide was generally well-tolerated. The study’s findings indicate semaglutide is a promising therapy for MASLD in individuals with HIV, contributing to healthier aging strategies for those living with the virus. Further research will explore potential immunological or inflammatory pathway changes associated with semaglutide therapy in people with HIV.

Source: asamonitor.pub/4aGhKYX